DMK Pharmaceuticals Corporation, along with its 5 affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on February 2, 2024. The debtor listed both its assets and liabilities in the range of $10 million to $50 million. The debtor is represented by Michael G. Busenkell of Gellert Scali Busenkell & Brown, LLC as its legal counsel.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0293 USD | -2.33% | -2.33% | -95.82% |
May. 30 | First Motion for Exclusivity Period Extension Filed by DMK Pharmaceuticals Corporation | CI |
May. 08 | Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation | CI |
1st Jan change | Capi. | |
---|---|---|
-95.82% | 303K | |
+42.34% | 739B | |
+32.96% | 598B | |
-5.25% | 353B | |
+17.85% | 318B | |
+5.03% | 285B | |
+16.49% | 240B | |
+9.52% | 210B | |
-5.19% | 206B | |
+8.10% | 164B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- DMK Pharmaceuticals Corporation Filed for Bankruptcy